These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

725 related articles for article (PubMed ID: 32699351)

  • 21. The use of BRM-activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients.
    Ebina T; Fujimiya Y; Yamaguchi T; Ogama N; Sasaki H; Isono N; Suzuki Y; Katakura R; Tanaka K; Nagata K; Takano S; Tamura K; Uno K; Kishida T
    Biotherapy; 1998; 11(4):241-53. PubMed ID: 9950100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human γδ T-Cells: From Surface Receptors to the Therapy of High-Risk Leukemias.
    Pistoia V; Tumino N; Vacca P; Veneziani I; Moretta A; Locatelli F; Moretta L
    Front Immunol; 2018; 9():984. PubMed ID: 29867961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition.
    Wrobel P; Shojaei H; Schittek B; Gieseler F; Wollenberg B; Kalthoff H; Kabelitz D; Wesch D
    Scand J Immunol; 2007; 66(2-3):320-8. PubMed ID: 17635809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gamma-delta (γδ) T cells: friend or foe in cancer development?
    Zhao Y; Niu C; Cui J
    J Transl Med; 2018 Jan; 16(1):3. PubMed ID: 29316940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses.
    Brandes M; Willimann K; Bioley G; Lévy N; Eberl M; Luo M; Tampé R; Lévy F; Romero P; Moser B
    Proc Natl Acad Sci U S A; 2009 Feb; 106(7):2307-12. PubMed ID: 19171897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells.
    Knight A; Mackinnon S; Lowdell MW
    Cytotherapy; 2012 Oct; 14(9):1110-8. PubMed ID: 22800570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Working in "NK Mode": Natural Killer Group 2 Member D and Natural Cytotoxicity Receptors in Stress-Surveillance by γδ T Cells.
    Silva-Santos B; Strid J
    Front Immunol; 2018; 9():851. PubMed ID: 29740448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antigen-Presenting Cell Characteristics of Human γδ T Lymphocytes in Chronic Myeloid Leukemia.
    Sawaisorn P; Tangchaikeeree T; Chan-On W; Leepiyasakulchai C; Udomsangpetch R; Hongeng S; Jangpatarapongsa K
    Immunol Invest; 2019 Jan; 48(1):11-26. PubMed ID: 30321079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of gammadelta T lymphocytes in tumor defense.
    Zocchi MR; Poggi A
    Front Biosci; 2004 Sep; 9():2588-604. PubMed ID: 15358583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gamma/delta T cells as cellular vehicles for anti-tumor immunity.
    Wang CQ; Lim PY; Tan AH
    Front Immunol; 2023; 14():1282758. PubMed ID: 38274800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The emerging Protumor role of γδ T lymphocytes: implications for cancer immunotherapy.
    Rei M; Pennington DJ; Silva-Santos B
    Cancer Res; 2015 Mar; 75(5):798-802. PubMed ID: 25660949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ex Vivo Expanded Human Vγ9Vδ2 T-Cells Can Suppress Epithelial Ovarian Cancer Cell Growth.
    Mao TL; Miao CH; Liao YJ; Chen YJ; Yeh CY; Liu CL
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Innate T cell immunity to HIV-infection. Immunotherapy with phosphocarbohydrates, a novel strategy of immune intervention?
    Gougeon ML; Malkovsky M; Casetti R; Agrati C; Poccia F
    Vaccine; 2002 May; 20(15):1938-41. PubMed ID: 11983250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.
    Viey E; Fromont G; Escudier B; Morel Y; Da Rocha S; Chouaib S; Caignard A
    J Immunol; 2005 Feb; 174(3):1338-47. PubMed ID: 15661891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Function of γδ T cells in tumor immunology and their application to cancer therapy.
    Park JH; Lee HK
    Exp Mol Med; 2021 Mar; 53(3):318-327. PubMed ID: 33707742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic avenues for γδ T cells in cancer.
    Costa GP; Mensurado S; Silva-Santos B
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38007241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. γδ T-cell immunotherapy for lung cancer.
    Yoshida Y; Nakajima J; Wada H; Kakimi K
    Surg Today; 2011 May; 41(5):606-11. PubMed ID: 21533930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin.
    Maeurer MJ; Martin D; Walter W; Liu K; Zitvogel L; Halusczcak K; Rabinowich H; Duquesnoy R; Storkus W; Lotze MT
    J Exp Med; 1996 Apr; 183(4):1681-96. PubMed ID: 8666926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells.
    Niu C; Jin H; Li M; Xu J; Xu D; Hu J; He H; Li W; Cui J
    BMC Immunol; 2015 Oct; 16():61. PubMed ID: 26458364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased frequencies of circulating and tumor-resident Vδ1
    Reboursiere E; Gac AC; Garnier A; Salaun V; Reman O; Pham AD; Cabrera Q; Khoy K; Vilque JP; Fruchart C; Chantepie S; Johnson-Ansah H; Macro M; Cheze S; Benabed K; Mear JB; Troussard X; Damaj G; Le Mauff B; Toutirais O
    Leuk Lymphoma; 2018 Jan; 59(1):187-195. PubMed ID: 28562153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.